Mesenchymal stem cells, implications for pain therapy

作     者：Elena Trallori Carla Ghelardini Lorenzo Di Cesare Mannelli 

作者机构：Dipartimento di Neuroscienze Psicologia Area del Farmaco e Salute del Bambino-Neurofarba-Sezione di Farmacologia e Tossicologia Università degli Studi di Firenze 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2019年第14卷第11期

页      面：1915-1916页

核心收录：

学科分类：0710[理学-生物学] 1001[医学-基础医学(可授医学、理学学位)] 10[医学] 

主　　题：mesenchymal stem cell (MSC) implications pain therapy 

摘      要：History and biology of mesenchymal stem cell (MSC): MSCs were firstly described around 1970s by Friedenstein and his collaborators as a subpopulation of colony forming, clonogenic, plastic adherent stromal bone marrow derived cells, with the capacity to regenerate other tissues (Murphy et al., 2013). Caplan (1991) proposed that these mesenchymal cells were “stem because of their ability to differentiate to any lineage of mesodermal cells. The richest sources of MSCs are bone marrow and adipose tissue, but they can also be isolated from synovial fluid, periosteum, fetal organs, placenta, umbilical cord blood and amniotic fluid (Murphy et al., 2013;Sherman et al., 2015).